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The treatment outcome in patients with extremity sarcomas has improved
considerably over the past 25 years due to advances in several disciplines. During
this period limb-saving procedures have replaced amputation as the primary mode of
surgical treatment. Pelvic sarcomas constitute a separate group of tumours due to
the complex anatomy, the large size of these tumours and the technical difficulties
often encountered at this anatomical site.
On the basis of 25 years of experience with the management of extremity sarcomas
at the University Hospital Groningen, the Netherlands, this thesis aimed: to discuss
the development and results of multidisciplinary treatment in extremity soft tissue
sarcoma and osteosarcoma; to investigate the long-term results of the combined
treatment of high-dose methotrexate-based neoadjuvant chemotherapy and surgery
in malignant fibrous histiocytoma of bone; to assess the long-term oncological and
functional outcome of endoprosthetic reconstructions after tumour resection of the
lower extremity; to investigate the indications and oncological results of hindfoot
amputation as a limb-sparing alternative to below-knee amputation; to inventorize the
indications and oncological results of two major amputations in surgical oncology:
interscapulothoracic amputation and hemipelvectomy; to analyse experience with
Tikhoff-Linberg resection as an alternative to interscapulothoracic amputation, as
well as internal hemipelvectomy with or without reconstruction and buttockectomy as
alternatives to hemipelvectomy; to investigate the oncological outcome of pelvic
osteosarcoma, which is a rare location for these tumours.
Chapter 2
Modern treatment strategies have resulted in improved local control and survival
rates in patients with extremity soft tissue sarcomas. Several important factors,
including improvements in imaging techniques, staging systems and the concept of
centralised treatment by multidisciplinary teams, have contributed to this favourable
outcome.
For local control of extremity soft tissue sarcoma, adequate surgical resection of the
primary tumour with tumour-free margins remains essential. In the past, conservative
local resection or shell-out procedures were associated with an unacceptable rate of
local recurrence, ranging from 60 to 95%. The application of radiotherapy has had a
major impact on the local control of soft tissue sarcomas and it is now being used
routinely in combination with conservative function-preserving and limb-sparing
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resection of the primary tumour. This treatment regimen of surgery and adjuvant
radiotherapy prevents local recurrence in up to g0% of cases. However, local control
after tumour resection is highly dependent on achieving negative surgical margins,
even with the addition of radiotherapy. improved understanding of tumour and
radiation biology has helped to determine the optimal radiation dose for the patient
and to decrease serious local complications. More recently, impressive local control
rates and an increasing number of limb-sparing resections were achieved in patients
with locally advanced extremity soft tissue sarcoma after using hyperthermic isolated
limb perfusion (HILP) including tumour necrosis factor-alpha (TNF-a) and melphalan.
Local control might increase even further with adjuvant radiotherapy after HILP
including TNF-q.
Chemotherapy has been disappointing in the management of soft tissue sarcoma.
There has been no convincing evidence that single agent or combination
chemotherapy has a positive effect on overall survival in patients with non-metastatic
soft tissue sarcoma, although disease-free survival seems to have lengthened.
For extremity soft tissue sarcomas, the most important prognostic factors for the
occurrence of local recurrence are surgical margins and tumour depth. Tumour
grade, tumour size and tumour depth emerged as important prognostic factors for
overall survival and the development of distant metastases. The causal relationship
between local recurrence and subsequent metastases and survival remains one of
the most controversial issues; this relationship has been questioned by several
authors. Presently, cytogenetics and molecular biology are being studied to detect
new prognostic markers with increasing impact.
Pulmonary metastases from soft tissue sarcoma are no longer considered to have a
uniformly fatal outcome, although the prognosis remains poor. After complete
resection of lung metastases, the S-year post-thoracotomy survival rate ranged from
20 to 40o/o. The contribution of adjuvant chemotherapy is stil l l imited.
Chapter 3
Over the past 25 years, the prognosis for osteosarcoma has improved significantly.
Until the early seventies, the S-year overall survival rates for patients with non-
metastatic osteosarcoma of the extremities were approximately 15 to 20%. Most
patients died of pulmonary metastases within 2 years of diagnosis. The observation
that doxorubicin and high-dose methotrexate resulted in (partial) necrosis of
metastasized osteosarcoma, led to the introduction of combination-chemotherapy for
primary non-metastatic osteosarcoma. Chemotherapy to eradicate the
micrometastases presumed to be present in 80% or more of patients at the time of
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initial diagnosis and adequate surgical resection of the primary tumour soon had a
major impact on the survival of patients with non-metastatic osteosarcoma. Due to
this combined treatment regimen, S-year disease-free survival and S-year overall
survival have increased to approximately 60% and 80%, respectively. The use of
effective neoadjuvant chemotherapy regimens, the development of improved
radiographic imaging techniques and advances in surgical procedures allowed
tumour resection with closer margins than before. As a consequence, amputation
has now been replaced by limb-saving procedures in most patients with extremity
osteosarcoma. As most patients with osteosarcoma re young and can be expected
to become long-term cancer survivors, the functional results and long-term integrity
of the reconstructions are of increasing interest and concern.
lmportant prognostic factors for osteosarcoma include tumour size, tumour location
and histological response to chemotherapy. Recently, new important biological
factors have been identified with increasing impact. The influence of these factors,
e.9., mutations in tumour-suppressor genes (p53, Rb) and overexpression of
oncogenes (MDM2, c-erb B-2), growth factors and cytokines (lGF-1, TGF-03), on
prognosis is being studied extensively. Furthermore, the correlation of several
mechanisms of multi-drug resistance (MDR), i.e., the phenomenon of simultaneous
resistance to structurally unrelated natural chemotherapeutic agents, with outcome is
being addressed in many recent trials. One of the most important mechanisms of
MDR identified up to now is the overexpression of P-glycoprotein (P-gp), a
transmembrane drug-efflux pump, that actively clears drugs from the cell. However,
resistance-modifying agents to circumvent drug resistance caused by P-gp have not
yet been successful in osteosarcoma.
lf pulmonary metastases develop after initial treatment, aggressive metastasectomy,
when feasible, is crucial to survival. lmportant prognostic factors are the number of
metastases, the use of salvage chemotherapeutic regimens, complete resection of
all metastases and the time to development of metasases.
Chapter 4
The value of high-dose methotrexate (HD-MTX)-based neoadjuvant chemotherapy
was evaluated in patients with malignant fibrous histiocytoma (MFH) of bone. Since
1977, MFH of bone has been diagnosed in 17 patients. Ten patients (59%)
completed treatment with 4 courses of neoadjuvant chemotherapy as follows: HD-
MTX, vincristine, adriamycin, cyclophosphamide, bleomycin and dactinomycin, or
HD-MTX, 41-epidoxorubicin a d carboplatin followed by localtumour esection (n=3),
curettage-cryosurgery (n=2), amputation (n=2), or tumour resection-endoprosthetic
d a
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replacement or allograft (n=3). After recovery from surgery, an additional 6 courses
of polychemotherapy, including HD-MTX in nine patients, were administered. One
patient changed to cisplatin instead of HD-MTX-containing chemotherapy
postoperatively. One additional patient received only adjuvant HD-MTX-containing
polychemotherapy. Neoadjuvant MTX-containing chemotherapy was contraindicated
in five patients (29%) due to age, cardiac insufficiency, or mental disorder. In one pa-
tient, neoadjuvant chemotherapy was stopped after 1 course due to renal failure.
Treatment consisted of amputation (n=2), 1 course of chemotherapy and amputation
(n=1), hyperthermic isolated limb perfussion (HILP; n=1), intra-arterialchemotherapy,
radiotherapy and endoprosthetic replacement (n=1) and a combination of
chemotherapy and radiotherapy (n=1). Five out of the six patients who did not
receive HD-MTX based neoadjuvant chemotherapy developed metastatic disease
(83%); the median time to the occurrence of metastatic disease was 17 months
(range, 3 to 44). In contrast, in the 10 patients who completed treatment with HD-
MTX-based neoadjuvant chemotherapy, with a mean follow-up of 9.8 years (range,
2.3 to 15.7) and a median follow-up of 10.8 years after diagnosis, no local recurrence
or distant metastases were diagnosed (P<.005).
It was concluded that neoadjuvant HD-MTX-containing chemotherapy in addition to
surgery dramatically improved the prognosis of patients with MFH of bone.
Chapter 5
Endoprosthetic replacement after resection of primary bone sarcomas of the lower
extremity is well-established. However, little is known about the specific long-term
consequences of these endoprosthetic reconstructions for the patients. Therefore,
the oncological results and the survival of the endoprostheses were reviewed in 32
patients with primary bone sarcoma of the femur or proximal tibia. There were 26
high-grade sarcomas and six low'grade sarcomas. A proximal femoral endo-
prosthesis was used for reconstruction in four patients, a total or push-through
femoralendoprosthesis in 11 pat ients,  a distal femoralendoprosthesis in 15 pat ients
and a proximal tibial endoprosthesis n two patients. Median survival was 10 years
(range, 1.1 to 18.9) for patients with high-grade sarcoma and 8.1 years (range,7 .1 to
10)for patients with low-grade sarcomas. Distant metastases developed in seven pa-
tients (22%), all with stage llB sarcoma, with concomitant local recurrence in three
patients (9%). Five-year overall survival and S-year disease-free survival for high-
grade sarcomas were 81% and 73%, respectively. The overall endoprosthetic
survival rate was 87% at 5 years, 80% at 10 years and 56% at 15 years. Median






























Endoprosthesis-related complications occurred in 13 patients @1%); most
complications were mechanical failures. The highest complication rate was found in
distal femoral replacements (60%). Five endoprostheses (16%) were revised.
Amputation of the involved limb was performed in four patients (13%): in two patients
because of local recurrence and in the other two patients because of infection after
implantation of a proximal tibial endoprosthesis. At follow-up, the median functional
Enneking evaluation score was 22 points (range, 12 to 28), with the highest
functional scores in patients with a distal femoral endoprosthesis and the lowest
functional scores in patients with total or push-through íemoral replacements.
It was concluded that endoprosthetic reconstructions gave satisfactory functional
results in most long-term survivors. However, the proximal tibial and distal femoral
endoprosthesis were at particular isk for long-term endoprosthetic omplications
requiring additional surgical procedures.
Chapter 6
The treatment for foot sarcomas is generally below-knee amputation. In selected
sarcomas of the forefoot, however, transtarsal amputation according to Chopart,
calcaneotibial arthrodesis according to Pirogoff, or supramalleolar amputation
according to Syme can be considered. These approaches lead to an optimal
functional outcome. Additionalcase histories are reported in this chapter.
Chapter 7
Nowadays, the majority of patients with bone or soft tissue sarcoma of the upper
extremity can be treated with limb-saving procedures using combined modality
therapies. However, in a small group of patients, interscapulothoracic amputation is
the only surgical treatment option with either a curative or a palliative intent. From
1972to 1991, interscapulothoracic amputation was performed on 12 patients, seven
males and five females, median age 36 years (range, 13 to 82). In five patients this
procedure was performed for bone sarcoma, in five for soft tissue sarcoma and in
two for locoregional metastases. There were no postoperative complications. During
a median follow-up of 8 years (range, 0.25 to 15), there were no local recurrences.
The S-year survival rate for soft tissue sarcoma was 80% and for bone sarcoma
30o/o.
It was concluded that interscapulothoracic amputation is a major ablative surgical
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Chapter I
Combined modality therapies with limb-saving procedures can be used in the
majority of patients with bone or soft tissue sarcoma of the upper extremity. In
patients with a tumour in the shoulder area, interscapulothoracic amputation might
be the only radical surgical treatment. However, in selected cases in which the
tumour does not involve the neurovascular bundle, a limb-sparing alternative might
be Tikhoff-Linberg resection. Normal function of the hand and forearm, with
reasonable function of the elbow, can be maintained by this procedure. Four case
histories are reported.
Chapter 9
The oncological and functional results after 11 external and 10 internal
hemipelvectomies and the consequences of limb-saving treatment were studied in
21 consecutive patients with primary bone (19 patients) or soft tissue sarcoma (two
patients) of the pelvic girdle. Following external hemipelvectomy, 10 patients (91%)
died after a median fol low-up of 1.6 years (range,0.3 to 7.1).  lsolated local
recurrences occurred in three patients (27%), with concomitant distant metastasis in
one (9%). Distant metastases without local recurrence developed in six patients
(55%). The rates of flap necrosis and wound infection following external
hemipelvectomy were both 25%. Following internal hemipelvectomy, nine patients
(90%) were alive without evidence of disease after a median follow-up of 6.6 years
(range, 2.3 to 16.0). Concomitant local and distant failures were found in one patient
(10%). Reconstruction-related complications necessitated salvage procedures in five
out of the seven patients (72o/o), and led to external hemipelvectomy inone.
Patients with a locally advanced pelvic girdle sarcoma who had to undergo external
hemipelvectomy had a poorer prognosis than those treated by internal
hemipelvectomy. Internal hemipelvectomy was not associated with an increased risk
of local failure. However, long-term local complications occurred, requiring extensive
surgical procedures.
Chapter 10
Reconstruction of the hip joint using a saddle prosthesis after excision of a malignant
pelvic tumour is a relatively new method, which in the past has mainly been used for
revision of infected hip arthroplasties. One patient with a metastatic ystosarcoma
phyllodes and one patient with a chondrosarcoma of the pelvis were treated by local
resection and reconstruction with a saddle prosthesis. Although the patient with the
metastatic cystosarcoma phyllodes died 9 months after surgery from metastatic
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disease, both patients had early recovery, with no difference in leg length and
accomplished early painless complete weight-bearing with satisfactory functional
results.
These two case reports il lustrate the usefulness of the saddle prosthesis in limb-
saving surgery for malignant tumours of the pelvis.
Chapter 11
Buttockectomy is an unusual surgical procedure for locally advanced soft tissue
sarcoma in the buttock region. Nine buttockectomy procedures were performed in
eight patients for primary (8) or recurrent (1) locally advanced soft tissue sarcoma of
the buttocks. Adjuvant external beam radiotherapy was applied within six weeks of
seven procedures. There were no postoperative complications, and no local
recurrences in this series. However, distant metastases developed in five patients
(63%) after a mean follow-up of 16 months (range, 6 to 25). Five-year overall survival
and S-year disease-free survival were 38% and 25o/o, respectively.
Buttockectomy with postoperative xternal beam radiotherapy may be an effective
limb-saving treatment to achieve local tumour control in selected soft tissue
sarcomas in the buttock region, without increased surgical and/or radiation-induced
morbidity.
Chapter 12
We reviewed the oncological outcome of 40 consecutive patients with an
osteosarcoma in the pelvic region registered in the files of the Netherlands
Committee on Bone Tumours between 1978 and 1995. Six patients had distant
metastases at initial presentation (Enneking stage lllB), 33 patients had stage llB
osteosarcoma nd one patient had stage lB osteosarcoma. Patients with metastases
were treated with chemotherapy (4) or palliative procedures (2). Patients with non-
metastatic osteosarcoma received surgery with (14) or without (4) (neo)adjuvant
chemotherapy, chemotherapy without surgical resection (9), or palliative treatment
(7). The median survival in stage llB and lllB osteosarcoma patients was 14 months
(range, 2to 175) and 7.5 months (range,2 to 16),  respect ively (P<.021).  Survival  in
patients with stage llB osteosarcoma treated with curative intent was significantly
better (p<.0006) than that in stage llB patients treated with palliative intent. Two and
S-year survival rates in patients with curatively treated stage llB osteosarcoma were
35% and 26%, respectively; distant metastases had developed in 65% of these
patients. Univariate analysis revealed the following positive prognostic factors in
patients with stage llB osteosarcoma: complaints of 3 months duration or shorter
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